Enhanced anabolic cytokine production and delivery system

US9833475B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9833475-B2
Application numberUS-201514970574-A
CountryUS
Kind codeB2
Filing dateDec 16, 2015
Priority dateMar 1, 2013
Publication dateDec 5, 2017
Grant dateDec 5, 2017

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Techniques and devices for removing (filtering out) unwanted/inhibitory components (for example, products, byproducts and/or cell output such as inhibitory catabolic proteins) from a composition (for example, autologous fluid or serum) containing such unwanted/inhibitory components. The devices include at least one construct designed to contain a composition (for example, autologous fluid or serum) containing inhibitory/unwanted components (products, byproducts and/or output of cells such as inhibitory catabolic proteins). The construct is provided with interior walls including specific protein capturing means designed to remove the inhibitory/unwanted component(s) (for example, specific protein(s)) from the composition. Proteins targeted for capture include, but are not limited to, catabolic cytokines such as IL-1β, IL-α, IL-6, TNFα, IFNγ and MMPS as these proteins inhibit the healing process.

First claim

Opening claim text (preview).

The invention claimed is: 1. A method for selectively removing unwanted components from a composition, comprising: introducing a composition into a construct having an internal wall construct formation coated with a capture antibody; passing the composition through the construct or incubating the composition within the construct to bind a catabolic cytokine and render a treated composition; and removing the treated composition from the construct. 2. The method as recited in claim 1 , comprising storing the treated composition in a refrigerator or freezer for later use to treat damaged tissue of a mammal. 3. The method as recited in claim 1 , wherein incubating the composition includes allowing the composition to sit in the construct for a set time period at room temperature to bind the catabolic cytokine. 4. The method as recited in claim 1 , wherein passing the composition through the construct includes passing the composition back and forth across the internal wall construct formation to bind the catabolic cytokine. 5. The method as recited in claim 1 , wherein the composition is a serum or an autologous fluid. 6. A catabolic cytokines removal system, comprising: a first syringe configured to hold a non-treated composition; a second syringe configured to hold a treated composition; and a tubing construct connected between the first syringe and the second syringe and including an internal wall coated with a capture antibody, the capture antibody configured to capture at least IL-1β as the non-treated composition is passed through the tubing construct to prepare the treated composition. 7. The system as recited in claim 6 , wherein the non-treated composition includes a first IL-1Ra/IL-1β ratio and the treated composition includes a second IL-1Ra/IL-1β ratio that is greater than the first IL-1Ra/IL-1β ratio. 8. The system as recited in claim 6 , comprising a formation on the internal wall that enlarges a surface area of the internal wall. 9. The system as recited in claim 8 , wherein the formation includes internal ribbing formed on the internal wall. 10. The system as recited in claim 6 , wherein the first syringe includes a second internal wall coated with a second capture antibody. 11. The method as recited in claim 1 , wherein the capture antibody comprises an anti-IL-1β antibody.

Assignees

Inventors

Classifications

  • Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

  • IL-1 · CPC title

  • for cytokines; for lymphokines; for interferons · CPC title

  • A61K35/16Primary

    Blood plasma; Blood serum (umbilical cord blood A61K35/51) · CPC title

  • Containers or vials which are to be joined to each other in order to mix their contents (combinations of vial and syringe for mixing their contents A61J1/2096) · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9833475B2 cover?
Techniques and devices for removing (filtering out) unwanted/inhibitory components (for example, products, byproducts and/or cell output such as inhibitory catabolic proteins) from a composition (for example, autologous fluid or serum) containing such unwanted/inhibitory components. The devices include at least one construct designed to contain a composition (for example, autologous fluid or se…
Who is the assignee on this patent?
Arthrex Inc
What technology area does this patent fall under?
Primary CPC classification A61K35/16. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Tue Dec 05 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).